Page 22 - Clinical Development News Today

In the heart of Montreal sits the non-profit organization Centech, a place that supports projects and startups with high growth potential – from conception right through to commercialization, which it says is thanks to a bold, collaborative, and passionate ecosystem.

Response Pharmaceuticals, Inc., has unveiled significant findings from its Phase 1b clinical trial of RDX-002, signaling a potential breakthrough in combatting antipsychotic-induced weight gain (AIWG).

Owlstone Medical, a global leader in Breath Biopsy for early disease detection and precision medicine, has announced a funding to the tune of $6.5 million.

OSP spoke to Berkeley Research Group healthcare managing director, Wendy Cheng for a discussion around developments in AI regulation for pharmaceuticals, clinical trials, and drug development at a global scale.

Provides full spectrum of clinical development services, including clinical strategy, project management, clinical operations, medical...

Zymeworks Inc. (NYSE:ZYME) Q1 2024 Earnings Call Transcript May 2, 2024 Zymeworks Inc. misses on earnings expectations. Reported EPS is $-0.41513 EPS, expectations were $-0.31. Zymeworks Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing by. […]

End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001...

June 16, 2024 PDUFA date for imetelstat NDA for the treatment of transfusion-dependent anemia in adult patients with lower-risk MDS ...

/PRNewswire/ -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases, today...

A significant milestone has been reached by Olden Labs as it steps into the limelight revealing its refreshing approach to animal research.